Anti-phospho-PTEN (Ser370)

Species Reactivity	Key Applications	Host	Format	Antibody Type
M	WB	Rb	Affinity Purified	Polyclonal Antibody

Species Reactivity

Key Applications

Host

Format

Antibody Type

Affinity Purified

Polyclonal Antibody

Description
Catalogue Number	07-889
Brand Family	Upstate
Trade Name	Upstate
Description	Anti-phospho-PTEN (Ser370) Antibody
Alternate Names	MMAC1 TEP1 mutated in multiple advanced cancers 1

Description

Catalogue Number

07-889

Brand Family

Upstate

Trade Name

Upstate

Description

Anti-phospho-PTEN (Ser370) Antibody

Alternate Names

MMAC1
TEP1
mutated in multiple advanced cancers 1

Product Information
Format	Affinity Purified
Presentation	100 μL of affinity purified rabbit polyclonal IgG in 50% storage buffer (PBS (without Mg²⁺ and Ca²⁺), pH 7.3 containing 1.0 mg/mL BSA (IgG, protease free) and 0.05% sodium azide) and 50% glycerol.

Product Information

Format

Affinity Purified

Presentation

100 μL of affinity purified rabbit polyclonal IgG in 50% storage buffer (PBS (without Mg²⁺ and Ca²⁺), pH 7.3 containing 1.0 mg/mL BSA (IgG, protease free) and 0.05% sodium azide) and 50% glycerol.

Applications
Application	Anti-phospho-PTEN (Ser370) Antibody is an antibody against phospho-PTEN (Ser370) for use in WB.
Key Applications	Western Blotting
Application Notes	Immunoblot Analysis: A 1:1000 dilution of this lot detected phospho-PTEN (Ser370) in RIPA lysates of 3T3-L1 cells.

Applications

Application

Anti-phospho-PTEN (Ser370) Antibody is an antibody against phospho-PTEN (Ser370) for use in WB.

Key Applications

Western Blotting

Application Notes

Immunoblot Analysis: A 1:1000 dilution of this lot detected phospho-PTEN (Ser370) in RIPA lysates of 3T3-L1 cells.

Biological Information
Immunogen	Peptide corresponding to amino acid region encompassing the human, mouse, and rat phospho-PTEN (Ser370)
Host	Rabbit
Specificity	Recognizes phosphorylated PTEN (Ser370)
Isotype	IgG
Species Reactivity	Mouse
Species Reactivity Note	Predicted to cross-react with human and rat based on 100 % sequence homology, but have not been tested.
Antibody Type	Polyclonal Antibody
Entrez Gene Number	NM_000314.4
Entrez Gene Summary	This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway.
Gene Symbol	PTEN TEP1 BZS MMAC1 PTEN1 MGC11227 MHAM
Modifications	Phosphorylation
Purification Method	Affinity Purfied
UniProt Number	P60484
UniProt Summary	FUNCTION: SwissProt: P60484 # Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine- phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3- phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K- AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. COFACTOR: Magnesium. SIZE: 403 amino acids; 47166 Da SUBUNIT: Monomer. The unphosphorylated form interacts with the second PDZ domain of AIP1 and with DLG1 and MAST2 in vitro. SUBCELLULAR LOCATION: Cytoplasm. TISSUE SPECIFICITY: Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas. DOMAIN: SwissProt: P60484 The C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function. PTM: Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit and promote PDZ-binding. DISEASE: SwissProt: P60484 # Mutations of PTEN are found in a large number of cancers. & Defects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD. & Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes. & Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Riley-Smith or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis. & Defects in PTEN are a cause of squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]. & Defects in PTEN are a cause of susceptibility to endometrial cancer [MIM:608089]. & Defects in PTEN are a cause of Proteus syndrome [MIM:176920]. Proteus syndrome is a hamartomatous disorder characterized by overgrowth of multiple tissues, connective tissue and epidermal naevi, and vascular malformations. These presentations are usually apparent at birth or soon after and continue to develop as the patient ages. It is named after the Greek god Proteus who, legend has it, could change his shape at will to avoid capture. Tumors, mostly benign but some malignant, have also been reported in Proteus syndrome, generally presenting by the age of 20 years and including papillary adenocarcinoma of the testis, meningioma, and cystadenoma of the ovaries. & Defects in PTEN are a cause of oligodendroglioma [MIM:137800]; also called oligodendroblastoma or familial glioma of brain. Oligodendroglioma is a usually benign neoplasm derived from and composed of oligodendrogliocytes in varying stages of differentiation. The majority are seen in adults in the white matter of the brain. & Defects in PTEN are a cause of VACTERL association with hydrocephalus [MIM:276950]; which includes also VATER association with hydrocephalus. VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. & Defects in PTEN are involved in prostate cancer [MIM:176807]. & Defects in PTEN are a cause of macrocephaly/autism syndrome [MIM:605309]. Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD). SIMILARITY: Contains 1 C2 tensin-type domain. & Contains 1 phosphatase tensin-type domain.
Molecular Weight	58 kDa

Biological Information

Immunogen

Peptide corresponding to amino acid region encompassing the human, mouse, and rat phospho-PTEN (Ser370)

Host

Rabbit

Specificity

Recognizes phosphorylated PTEN (Ser370)

Isotype

IgG

Species Reactivity

Mouse

Species Reactivity Note

Predicted to cross-react with human and rat based on 100 % sequence homology, but have not been tested.

Antibody Type

Polyclonal Antibody

Entrez Gene Number

NM_000314.4

Entrez Gene Summary

This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway.

Gene Symbol

PTEN
TEP1
BZS
MMAC1
PTEN1
MGC11227
MHAM

Modifications

Phosphorylation

Purification Method

Affinity Purfied

UniProt Number

P60484

UniProt Summary

FUNCTION: SwissProt: P60484 # Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine- phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3- phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K- AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue.

COFACTOR: Magnesium.

SIZE: 403 amino acids; 47166 Da

SUBUNIT: Monomer. The unphosphorylated form interacts with the second PDZ domain of AIP1 and with DLG1 and MAST2 in vitro.

SUBCELLULAR LOCATION: Cytoplasm.

TISSUE SPECIFICITY: Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.

DOMAIN: SwissProt: P60484 The C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function.

PTM: Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit and promote PDZ-binding.

DISEASE: SwissProt: P60484 # Mutations of PTEN are found in a large number of cancers. & Defects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD. & Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes. & Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Riley-Smith or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis. & Defects in PTEN are a cause of squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]. & Defects in PTEN are a cause of susceptibility to endometrial cancer [MIM:608089]. & Defects in PTEN are a cause of Proteus syndrome [MIM:176920]. Proteus syndrome is a hamartomatous disorder characterized by overgrowth of multiple tissues, connective tissue and epidermal naevi, and vascular malformations. These presentations are usually apparent at birth or soon after and continue to develop as the patient ages. It is named after the Greek god Proteus who, legend has it, could change his shape at will to avoid capture. Tumors, mostly benign but some malignant, have also been reported in Proteus syndrome, generally presenting by the age of 20 years and including papillary adenocarcinoma of the testis, meningioma, and cystadenoma of the ovaries. & Defects in PTEN are a cause of oligodendroglioma [MIM:137800]; also called oligodendroblastoma or familial glioma of brain. Oligodendroglioma is a usually benign neoplasm derived from and composed of oligodendrogliocytes in varying stages of differentiation. The majority are seen in adults in the white matter of the brain. & Defects in PTEN are a cause of VACTERL association with hydrocephalus [MIM:276950]; which includes also VATER association with hydrocephalus. VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects. & Defects in PTEN are involved in prostate cancer [MIM:176807]. & Defects in PTEN are a cause of macrocephaly/autism syndrome [MIM:605309]. Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD).

SIMILARITY: Contains 1 C2 tensin-type domain. & Contains 1 phosphatase tensin-type domain.

Molecular Weight

58 kDa

Product Usage Statements
Quality Assurance	Routinely evaluated by immunoblot.
Usage Statement	Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Product Usage Statements

Quality Assurance

Routinely evaluated by immunoblot.

Usage Statement

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage and Shipping Information
Storage Conditions	Stable for 2 years at -20°C from date of shipment. Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerolcontaining solutions to become frozen during storage.

Storage and Shipping Information

Storage Conditions

Stable for 2 years at -20°C from date of shipment.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerolcontaining solutions to become frozen during storage.

Packaging Information
Material Size	100 µL

Packaging Information

Material Size

100 µL

实验耗材

分子生物学试剂

蛋白与免疫学

生化试剂

细胞及检测试剂

色谱及层析

仪器设备

实验服务

办公用品

Anti-phospho-PTEN (Ser370)

浏览了该商品的用户最终购买

浏览了该商品的用户还浏览了

特卖

重要规格表

我要咨询